2018

• business2018/12/25

  Kyn Therapeutics Initiates Phase 1b/2 Clinical Studies of AAT-007 in Collaboration with Merck

  AskAt Inc. (AskAt) (Headquarters: Nagoya, Japan, CEO: Akihiro Furuta) announced today that Kyn Therapeutics, Inc. (Headquarters: Cambridge, Massachusetts, CEO: Mark Manfredi) has initiated clinical studies of AAT-007 (grapiprant/ARY-007) in combination with pembrolizumab (anti-PD-1 antibody, KEYTRUDA®) in patients with colorectal cancer and non-small cell lung cancer. AskAt licensed AAT-007 in immuno-oncology to Arrys Therapeutics, now a wholly-owned subsidiary of Kyn Therapeutics, in December 2017. For more information, visit Kyn web.

• patent2018/12/20

  China National Intellectual Property Administration Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist

  AskAt received a notice of allowance dated November 16, 2018 from China National Intellectual Property Administration (CNIPA) in connection with the Application No. 201480017059.X, a cartilage disease use patent of EP4 antagonist.

• patent2018/12/20

  NASH-Associated Liver Cancer Use Patent for EP4 Receptor Antagonists Approved in Canada

  AskAt received a notice of allowance dated December 11, 2018 from Canadian Intellectual Property Office (CIPO) in connection with the Application No. 3,000,237, Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer.

• patent2018/11/06

  Japan Patent Office Granted AskAt a Use Patent of COX-2 Inhibitor (AAT-076) for Ocular Diseases

  AskAt Inc. announced today that AskAt received a notice of allowance dated October 2, 2018 from Japan Patent Office in connection with the Application No. 2015-508830, a use patent of COX-2 inhibitor (AAT-076) for ocular diseases.

• business2018/10/02

  Arrys Therapeutics Initiates CRC Clinical Study with AAT-007 and Pembrolizumab

  AskAt Inc. (AskAt) (Headquarters: Nagoya, Japan, CEO: Akihiro Furuta) announced today that Arrys Therapeutics, Inc. (Headquarters: Cambridge, Massachusetts), which licensed AAT-007 in immuno-oncology from AskAt in December 2017, has initiated a clinical study with AAT-007 (grapiprant) (ARY-007) in combination with pembrolizumab (anti PD-1 antibody, KEYTRUDA®).

• business2018/09/26

  EP4 Antagonist AAT-007 Clinical Study Initiated in the People's Republic of China

  RMX Biopharma Co., Ltd (Headquartered in Hangzhou, China, CEO: RuiPing Dong, "RMX"), initiated a clinical study with EP4 antagonist AAT-007 in the People’s Republic of China (China) on September 20, 2018. RMX licensed AskAt Inc.’s EP4 antagonist AAT-007 (generic name: grapiprant) for pain indications in China on January 1, 2016.
  This is the first clinical trial in China. AAT-007 has previously demonstrated efficacy, safety, and tolerability in Phase 2 clinical trials in the United States for osteoarthritis-associated pain.

• patent2018/09/19

  European Patent Office Granted AskAt a Use Patent of EP4 Receptor Antagonist for the Treatment of Cancer

  AskAt Inc. announced today that AskAt received the decision to grant a European patent dated September 13, 2018 from the European Patent Office (EPO) in connection with the Application No. 15182580.9, a use patent of EP4 receptor antagonist for the treatment of Cancer.

• business2018/09/03

  Headquarters relocation

  We are pleased to inform you that the headquarters has moved to the following address on August 27.
  New address: 2F Dai-Tokai Bldg., 3-22-8 Meieki, Nakamura-ku, Nagoya, Aichi 450-0002, Japan.

• patent2018/08/25

  European Patent Office Granted AskAt a Salt & Crystal Forms Patent of COX-2 Inhibitor (AAT-076)

  AskAt, Inc. announced today that AskAt received the decision to grant a European patent dated August 17, 2018 from the European Patent Office (EPO) in connection with the Application No., 14733062.5 a salt and crystal forms patent for its COX-2 Inhibitor (AAT-076).

• patent2018/08/13

  Dementia Use Patent for 5-HT4 Receptor Agonist (AAT-009) Approved in Canada

  AskAt received a notice of allowance dated July 19, 2018 from Canadian Intellectual Property Office (CIPO) in connection with the Application No. 2,789,663, a use patent of 5-HT4 receptor agonist for dementia.

• patent2018/07/30

  Substance Patent for 5-HT4 Receptor Agonist (AAT-009) Approved in Brazil

  AskAt Inc. announced today that the allowance of a substance patent for its 5-HT4 Receptor Agonist (AAT-009), Application No. PI0414105-9 was noticed from Brazilian Patent Office.

• patent2018/07/19

  Ocular Diseases Use Patent for COX-2 Inhibitor (AAT-076) Approved in Europe

  AskAt received Decision to grant a European patent pursuant to Article 97(1) EPC dated July 5, 2018 from European Patent Office (EPO) in connection with the Application No. 14 775 889.0, a use patent of COX-2 inhibitor (AAT-076) for ocular diseases.

• business2018/07/19

  Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China

  Ningbo NewBay Medical Technology Co., Ltd. (headquarters in Ningbo, China, CEO: Zhenhai Shen, “NewBay”) received an approval of an IND application for EP4 antagonist AAT-007 (grapiprant) for cancer therapy from China Food and Drug Administration (“CFDA”) on July 4, 2018. NewBay is a subsidiary company of Ningbo Tai Kang Co., Ltd. to which AskAt Inc. licensed AAT-007 for cancer therapy in China. NewBay submitted the IND application to CFDA on January 16, 2018.

• patent2018/05/08

  Rospatent Granted AskAt a Salt & Crystal Forms Patent of COX-2 Inhibitor

  AskAt Inc. announced today that AskAt received a notice of allowance dated April 3, 2018 from Rospatent (Federal Service for Intellectual Property, Patents & Trademarks of Russia) in connection with the Application No. 2015130602, a salt and crystal forms patent for its COX II Inhibitor (AAT-076).

• patent2018/04/17

  Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist

  AskAt Inc. announced today that AskAt received a notice of allowance dated April 17, 2018 from Japan Patent Office in connection with the Application No. 2015-545594, a cartilage disease use patent of EP4 antagonist.

• business2018/03/01

  AskAt Inc. and Aratana Therapeutics, Inc. Announce Global Collaboration in Animal Health Initial Focus to be Innovative EP4 Antagonist AAT-008

  March 1, 2018 - AskAt Inc. (headquartered in Nagoya, Japan) (AskAt) and Aratana Therapeutics, Inc. (headquartered in Leawood, Kansas) (Aratana) today announced a collaboration to create a groundbreaking innovation platform in animal health. The companies will jointly pursue research and development in animal health treatment with a series of compounds developed by AskAt for human health.

• business2018/02/08

  AskAt Inc. Announces EP4 Antagonist Immuno-Oncology License Agreement with NewBay Medical Technology Co., Ltd.

  AskAt Inc. (AskAt), headquartered in Nagoya, Japan, today announced a license agreement with NewBay Medical Technology Co., Ltd. (NewBay), headquartered in Hangzhouwan New Zone, Ningbo, Zhejiang Province, People’s Republic of China (China), granting NewBay exclusive rights to develop, manufacture and commercialize AskAt’s EP4 Antagonist [AAT-008] in China in the area of Immuno-Oncology.

• business2018/02/01

  Annual Sales of Galliprant Reach (US) $23 million

  January 31, 2018 (US time) Eli Lilly and Company (Headquartered in Indiana, United States) (Lilly) announced in financial reporting to investors that the company’s EP4 Antagonist (Galliprant/grapiprant/RQ-00000007/AT-001) achieved 2017 fourth quarter sales of (US) $8 million, a 29 percent increase over third quarter sales, and (US) $23 million in 2017 fiscal year sales, which represents 12 percent of the US non-steroidal anti-inflammatory therapy animal health market.

• business2018/01/22

  Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China

  Ningbo NewBay Medical Technology Co., Ltd. (Headquarters in Ningbo, China, CEO: Zhenhai Shen, NewBay), a subsidiary company of Ningbo Tai Kang Medical Technology Co., Ltd (“Ningbo Tai Kang”), which licensed AskAt Inc.’s EP4 antagonist AAT-007 (generic name: grapiprant) for oncology in China, has filed an IND application with the China Food and Drug Administration.
  

• business2018/01/19

  GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017

  January 18, 2017 (US time) –Aratana Therapeutics Inc. (hereinafter called “Aratana”) have announced that Galliprant® (EP4 antagonist /grapiprant/RQ-00000007/AT-001, hereinafter called “Galliprant”) was named Animal Pharm's Best Companion Animal Product for 2017.

• business2018/01/12

  Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe

  LEAWOOD, Kan., Jan. 11, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
  
  Galliprant is a new veterinary medicine that will be indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug. Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States.
  
  Aratana HP;
  http://aratana.investorroom.com/2018-01-11-Elanco-Aratana-Announce-Marketing-Authorization-of-GALLIPRANT-R-grapiprant-tablets-in-Europe
  
  
  

• business2018/01/04

  Investigational new drug application for next generation COX-2 inhibitor AAT-076 has been accepted by the National Food and Drug Administration of the People's Republic of China

  RMX Biopharma Co., Ltd (Headquarters in Hangzhou, China, CEO: RuiPing Dong, RMX), which licensed AskAt’s COX-2 inhibitor AAT-076 for pain indications in People’s Republic of China (China), submitted an investigational new drug (IND) application to the State Food and Drug Administration and Supervision Authority of China (CFDA) has been accepted.